SE9501567D0 - A new combination - Google Patents

A new combination

Info

Publication number
SE9501567D0
SE9501567D0 SE9501567A SE9501567A SE9501567D0 SE 9501567 D0 SE9501567 D0 SE 9501567D0 SE 9501567 A SE9501567 A SE 9501567A SE 9501567 A SE9501567 A SE 9501567A SE 9501567 D0 SE9501567 D0 SE 9501567D0
Authority
SE
Sweden
Prior art keywords
composition
component
disorders
new combination
phthalancarbonitrile
Prior art date
Application number
SE9501567A
Other languages
English (en)
Swedish (sv)
Inventor
John Evenden
Seth-Olov Thorberg
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9501567A priority Critical patent/SE9501567D0/xx
Publication of SE9501567D0 publication Critical patent/SE9501567D0/xx
Priority to TW085104481A priority patent/TW458777B/zh
Priority to ZA962982A priority patent/ZA962982B/xx
Priority to IL11798896A priority patent/IL117988A0/xx
Priority to BR9608252A priority patent/BR9608252A/pt
Priority to ES96912370T priority patent/ES2175089T3/es
Priority to AU55202/96A priority patent/AU696356C/en
Priority to HK98101990.1A priority patent/HK1002853B/en
Priority to NZ306602A priority patent/NZ306602A/en
Priority to PT96912370T priority patent/PT822813E/pt
Priority to SK1429-97A priority patent/SK282060B6/sk
Priority to CN96194810A priority patent/CN1102386C/zh
Priority to PL96323083A priority patent/PL183997B1/pl
Priority to KR1019970707592A priority patent/KR100419810B1/ko
Priority to TR97/01254T priority patent/TR199701254T1/xx
Priority to EE9700245A priority patent/EE03553B1/xx
Priority to DK96912370T priority patent/DK0822813T3/da
Priority to JP8532425A priority patent/JPH11504037A/ja
Priority to RU97119427/14A priority patent/RU2183955C2/ru
Priority to PCT/SE1996/000526 priority patent/WO1996033710A1/en
Priority to CA002218181A priority patent/CA2218181A1/en
Priority to SI9630486T priority patent/SI0822813T1/xx
Priority to AT96912370T priority patent/ATE216579T1/de
Priority to US08/640,896 priority patent/US5962514A/en
Priority to CZ973356A priority patent/CZ335697A3/cs
Priority to EP96912370A priority patent/EP0822813B1/en
Priority to HU9801946A priority patent/HUP9801946A3/hu
Priority to DE69620878T priority patent/DE69620878T2/de
Priority to ARP960102323A priority patent/AR002990A1/es
Priority to YU25696A priority patent/YU25696A/sh
Priority to IS4585A priority patent/IS1821B/is
Priority to NO19974921A priority patent/NO317057B1/no
Priority to US09/349,590 priority patent/US6184218B1/en
Priority to US09/351,069 priority patent/US6169098B1/en
Priority to US09/351,071 priority patent/US6184219B1/en
Priority to US09/351,070 priority patent/US6172105B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
SE9501567A 1995-04-27 1995-04-27 A new combination SE9501567D0 (sv)

Priority Applications (36)

Application Number Priority Date Filing Date Title
SE9501567A SE9501567D0 (sv) 1995-04-27 1995-04-27 A new combination
TW085104481A TW458777B (en) 1995-04-27 1996-04-15 Pharmaceutical compositions for treating affective disorders
ZA962982A ZA962982B (en) 1995-04-27 1996-04-15 A new combination
IL11798896A IL117988A0 (en) 1995-04-27 1996-04-21 A new combination of an inhibitor and an antagonist
DE69620878T DE69620878T2 (de) 1995-04-27 1996-04-23 Kombination eines 5-ht uptakeinibitors mit einem selektiven 5-ht 1a antagonisten
DK96912370T DK0822813T3 (da) 1995-04-27 1996-04-23 Kombination af en 5-HT-optagelsesinhibitor med en selektiv 5-HT 1A-antagonist
PCT/SE1996/000526 WO1996033710A1 (en) 1995-04-27 1996-04-23 A combination of a 5-ht uptake inhibitor with a selective 5-ht1a antagonist
AU55202/96A AU696356C (en) 1995-04-27 1996-04-23 A combination of a 5-HT uptake inhibitor with a selective 5-HT1A antagonist
HK98101990.1A HK1002853B (en) 1995-04-27 1996-04-23 A combination of a 5-ht uptake inhibitor with a selective 5-ht1a antagonist
NZ306602A NZ306602A (en) 1995-04-27 1996-04-23 A fast onset combination of a 5-ht-reuptake inhibitor and a selective 5-ht1a antagonist in its r-enantiomer form such as 5-carbamoyl-8-fluoro-3,4-dihydro-2h-1-benzopyran derivative
PT96912370T PT822813E (pt) 1995-04-27 1996-04-23 Combinacao de um inibidor da absorcao de 5-ht com um antagonista de 5-ht1a selectivo
SK1429-97A SK282060B6 (sk) 1995-04-27 1996-04-23 Kombinácia inhibítora spätnej absorpcie 5-ht so selektívnou protilátkou 5-ht1a, spôsob jej prípravy, farmaceutická formulácia s jej obsahom, jej použitie a kit s jej obsahom
CN96194810A CN1102386C (zh) 1995-04-27 1996-04-23 5－ht摄取抑制剂与选择性5－ht1a拮抗剂的组合物
PL96323083A PL183997B1 (pl) 1995-04-27 1996-04-23 Środek farmaceutyczny oraz zastosowanie połączenia inhibitora wychwytu zwrotnego 5-HT i selektywnego antagonisty 5-HT
KR1019970707592A KR100419810B1 (ko) 1995-04-27 1996-04-23 5-ht흡수억제제와선택성5-ht1a길항제의조합물
TR97/01254T TR199701254T1 (xx) 1995-04-27 1996-04-23 5-HT al�� inhibit�r�n�n selektif 5-HT1A antagonistiyle kombinasyonu.
EE9700245A EE03553B1 (et) 1995-04-27 1996-04-23 5-HT tagasihaarde inhibiitori kombinatsioon selektiivse 5-HT1A antagonistiga
BR9608252A BR9608252A (pt) 1995-04-27 1996-04-23 Combinação de um primeiro componente que é um inibidor de reabsorção de 5-ht e um segundo componente que é antagonista de 5-th uso da combinação processos para o tratamento de disúrbios efetivos e da depressão para a preparaç o da combinaç o e para melhoria do início de ação terapéutica formulação farmacéutica para o suo no tratamento de distúrbios efetivos e kit
JP8532425A JPH11504037A (ja) 1995-04-27 1996-04-23 ５−ｈｔ取り込み阻害薬と選択的５−ｈｔ▲下１ａ▼アンタゴニストとの組み合わせ
RU97119427/14A RU2183955C2 (ru) 1995-04-27 1996-04-23 Сочетание ингибитора усвоения 5-нт с селективным 5-нт1a антагонистом
ES96912370T ES2175089T3 (es) 1995-04-27 1996-04-23 Una combinacion de un inhibidor de la absorcion de 5 - ht con un ant agonista selectivo de 5 ht1a.
CA002218181A CA2218181A1 (en) 1995-04-27 1996-04-23 A combination of a 5-ht uptake inhibitor with a selective 5-ht1a antagonist
SI9630486T SI0822813T1 (en) 1995-04-27 1996-04-23 A combination of a 5-ht uptake inhibitor with a selective 5-ht 1a antagonist
AT96912370T ATE216579T1 (de) 1995-04-27 1996-04-23 Kombination eines 5-ht uptakeinibitors mit einem selektiven 5-ht 1a antagonisten
US08/640,896 US5962514A (en) 1995-04-27 1996-04-23 Combination of 5-HT uptake inhibitor with a selective 5-HT1A antagonist
CZ973356A CZ335697A3 (cs) 1995-04-27 1996-04-23 Směs 5-HT inhibitoru se selektivním 5-HT 1A antagonistem a farmaceutický prostředek, který je obsahuje
EP96912370A EP0822813B1 (en) 1995-04-27 1996-04-23 A combination of a 5-ht uptake inhibitor with a selective 5-ht 1a antagonist
HU9801946A HUP9801946A3 (en) 1995-04-27 1996-04-23 A combination al medicament containing a 5-ht uptake inhibitor and a selective 5-ht1a antagonist and process for producing it
ARP960102323A AR002990A1 (es) 1995-04-27 1996-04-25 Una nueva combinacion de un inhibidor de reabsorcion de 5-ht y un antagonista 5-ht(1a), su uso para la preparacion de medicamentos, una formulacion farmaceutica que la comprende, un procedimiento para la preparacion de dicha combinacion y equipo que contiene dicha combinacion.
YU25696A YU25696A (sh) 1995-04-27 1996-04-26 Postupak dobijanja kombinacije (r)-5-karbamoil-8-fluoro-3- n,n-disupstituisan-amino-3,4-dihloro-2h-1-bezopirana i farmaceutske formulacije koje ih sadrže
IS4585A IS1821B (is) 1995-04-27 1997-10-09 Samsetning 5-HT upptöku-hemils og valkvæðs 5-HT 1A -mótlyfs
NO19974921A NO317057B1 (no) 1995-04-27 1997-10-24 Kombinasjon av en 5-HT-opptaksinhibitor med en selektiv 5-HT<N>1A</N> antagonist, formulering og kit inneholdende en slik kombinasjon, fremgangsmate for dens fremstilling, og anvendelse derav.
US09/349,590 US6184218B1 (en) 1995-04-27 1999-07-09 Composition and methods employing it for the treatment of 5-HT-mediated disorders
US09/351,069 US6169098B1 (en) 1995-04-27 1999-07-09 Composition and methods employing it for the treatment of 5-HT-mediated disorders
US09/351,071 US6184219B1 (en) 1995-04-27 1999-07-09 Composition and methods employing it for the treatment of 5-HT-mediated disorders
US09/351,070 US6172105B1 (en) 1995-04-27 1999-07-09 Composition and methods employing it for the treatment of 5-HT-mediated disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9501567A SE9501567D0 (sv) 1995-04-27 1995-04-27 A new combination

Publications (1)

Publication Number Publication Date
SE9501567D0 true SE9501567D0 (sv) 1995-04-27

Family

ID=20398119

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9501567A SE9501567D0 (sv) 1995-04-27 1995-04-27 A new combination

Country Status (29)

Country Link
US (5) US5962514A (cs)
EP (1) EP0822813B1 (cs)
JP (1) JPH11504037A (cs)
KR (1) KR100419810B1 (cs)
CN (1) CN1102386C (cs)
AR (1) AR002990A1 (cs)
AT (1) ATE216579T1 (cs)
BR (1) BR9608252A (cs)
CA (1) CA2218181A1 (cs)
CZ (1) CZ335697A3 (cs)
DE (1) DE69620878T2 (cs)
DK (1) DK0822813T3 (cs)
EE (1) EE03553B1 (cs)
ES (1) ES2175089T3 (cs)
HU (1) HUP9801946A3 (cs)
IL (1) IL117988A0 (cs)
IS (1) IS1821B (cs)
NO (1) NO317057B1 (cs)
NZ (1) NZ306602A (cs)
PL (1) PL183997B1 (cs)
PT (1) PT822813E (cs)
RU (1) RU2183955C2 (cs)
SE (1) SE9501567D0 (cs)
SK (1) SK282060B6 (cs)
TR (1) TR199701254T1 (cs)
TW (1) TW458777B (cs)
WO (1) WO1996033710A1 (cs)
YU (1) YU25696A (cs)
ZA (1) ZA962982B (cs)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination
SE9703374D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
WO1999061014A2 (en) * 1998-05-28 1999-12-02 Sepracor Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
SE9803158D0 (sv) * 1998-09-16 1998-09-16 Astra Ab A new composition
SE9803155D0 (sv) * 1998-09-16 1998-09-16 Astra Ab A new composition
SE9803157D0 (sv) * 1998-09-16 1998-09-16 Astra Ab A new composition
SE9803156D0 (sv) * 1998-09-16 1998-09-16 Astra Ab A new composition
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
US6331233B1 (en) 2000-02-02 2001-12-18 Honeywell International Inc. Tantalum sputtering target with fine grains and uniform texture and method of manufacture
ATE334979T1 (de) 2000-10-13 2006-08-15 Neurosearch As Behandlung affektiver störungen durch kombinierte wirkung eines nikotinischen rezeptoragonisten und einer monoaminergischen substanz
US20030185754A1 (en) * 2001-01-16 2003-10-02 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
US20030166554A1 (en) * 2001-01-16 2003-09-04 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
KR20100012089A (ko) * 2001-05-01 2010-02-05 하. 룬트벡 아크티에 셀스카브 경상이성체성 순수 에스시탈로프람의 용도
US7034059B2 (en) 2001-07-02 2006-04-25 Sepracor Inc. Methods of using norfluoxetine
US6855735B2 (en) 2002-03-20 2005-02-15 Temple University Of The Commonwealth System Of Higher Education Ketamine treatment of restless legs syndrome
RU2340333C2 (ru) * 2002-08-15 2008-12-10 Вайет Агонизм 5нт2a -рецептора для лечения нарушения функции терморегуляции
US20050032873A1 (en) * 2003-07-30 2005-02-10 Wyeth 3-Amino chroman and 2-amino tetralin derivatives
US7695601B2 (en) * 2006-05-09 2010-04-13 The United States Of America As Represented By The Secretary Of The Army Electrochemical test apparatus and method for its use
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
EP3019865A4 (en) * 2013-07-12 2017-04-05 Immuneering Corporation Systems, methods, and environment for automated review of genomic data to identify downregulated and/or upregulated gene expression indicative of a disease or condition
CA3049464A1 (en) 2017-02-14 2018-08-23 Research Triangle Institute Proline-based neuropeptide ff receptor modulators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4698342A (en) * 1985-07-16 1987-10-06 Serotonin Industries Of Charleston Method and compositions for controlling pain, depression and sedation
US5616610A (en) * 1989-12-22 1997-04-01 Astra Aktiebolag (R)-5-carbamoyl-8-fluoro-3-N,N-disubstituted-amino-3,4-dihydro-2H-1-benzopyrans
US5420151A (en) * 1989-12-22 1995-05-30 Aktiebolaget Astra Chroman derivatives
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination

Also Published As

Publication number Publication date
US6172105B1 (en) 2001-01-09
TW458777B (en) 2001-10-11
HUP9801946A3 (en) 2000-12-28
HUP9801946A2 (hu) 2000-05-28
EP0822813A1 (en) 1998-02-11
NO974921D0 (no) 1997-10-24
DE69620878D1 (de) 2002-05-29
ZA962982B (en) 1996-10-28
AU696356B2 (en) 1998-09-10
DE69620878T2 (de) 2002-11-14
CZ335697A3 (cs) 1998-06-17
IL117988A0 (en) 1996-08-04
AU5520296A (en) 1996-11-18
US6169098B1 (en) 2001-01-02
PL183997B1 (pl) 2002-08-30
EE9700245A (et) 1998-04-15
IS4585A (is) 1997-10-09
IS1821B (is) 2002-08-27
CN1102386C (zh) 2003-03-05
JPH11504037A (ja) 1999-04-06
NO974921L (no) 1997-12-18
US5962514A (en) 1999-10-05
BR9608252A (pt) 1999-05-04
KR19990008068A (ko) 1999-01-25
EE03553B1 (et) 2001-12-17
US6184219B1 (en) 2001-02-06
SK142997A3 (en) 1998-12-02
YU25696A (sh) 1999-06-15
AR002990A1 (es) 1998-05-27
TR199701254T1 (xx) 1998-02-21
RU2183955C2 (ru) 2002-06-27
HK1002853A1 (en) 1998-09-25
CA2218181A1 (en) 1996-10-31
ES2175089T3 (es) 2002-11-16
SK282060B6 (sk) 2001-10-08
KR100419810B1 (ko) 2004-04-21
US6184218B1 (en) 2001-02-06
NO317057B1 (no) 2004-08-02
CN1187768A (zh) 1998-07-15
WO1996033710A1 (en) 1996-10-31
EP0822813B1 (en) 2002-04-24
PT822813E (pt) 2002-10-31
NZ306602A (en) 1999-04-29
DK0822813T3 (da) 2002-07-29
PL323083A1 (en) 1998-03-02
ATE216579T1 (de) 2002-05-15

Similar Documents

Publication Publication Date Title
SE9501567D0 (sv) A new combination
ATE203019T1 (de) Neue (r)-5-carbamoyl-8-fluor-3-n,n- disubstituierte-amino-3,4-dihydro-2h-1- benzopyrane
MY125414A (en) Aminopropylphosphinic acids
EA200700232A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
DE602006021444D1 (de) Therapie zur behandlung der überaktiven blase
RU97119427A (ru) Сочетание ингибитора усвоения 5-нт с селективным 5-нтia антагонистом
BR9810773A (pt) Uso de um ingrediente anestésico local de ação prolongada, composição farmacêutica, uso de um anestésico local, e, kit
AR015448A1 (es) COMBINACIoN DE UN INHIBIDOR DE REABSORCIoN DE 5-HT CON UN ANTAGONISTA O AGONISTA PARCIAL DE H5-HT1B, PROCESO PARA SU PREPARACIoN, FORMULACIoN FARMACÉUTICA QUE LA CONTIENE, SU USO PARA PREPARAR MEDICAMENTOS PARA TRATAR TRASTORNOS AFECTIVOS Y KIT QUE CONTIENE DICHA COMBINACIoN
SE0102055D0 (sv) New Compounds
SE0104331D0 (sv) Novel compounds
ATE369348T1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
EP1254668A3 (en) Combination of a serotonin reuptake inhibitor and a GABA-A alpha 2/3 agonist for use in anxiety and depression
WO2004096118A3 (en) Composition for improving cognition and memory
SE9803157D0 (sv) A new composition
MXPA02011554A (es) Combinacion de secretagogos de hormona del crecimiento y antidepresivos.
SE9702066D0 (sv) A new salt
SE9804126D0 (sv) New pharmaceutical composition
EA200400302A1 (ru) Способ лечения первичной бессонницы
HUP9601680A2 (hu) Benzizotiazolil-szubsztituált amino-metil-krománok, az ezeket tartalmazó gyógyszerkészítmények, eljárás előállításukra és a vegyületek alkalmazása
ATE289583T1 (de) Stereoisomere von propyl-isopropylacetamid, verfahren zu deren herstellung sowie diese enthaltende pharmazeutische zubereitungen
SE9803158D0 (sv) A new composition
SE9803156D0 (sv) A new composition
MXPA05008711A (es) Uso de r-10-hidroxi-10,11-dihidro-carbamazepina en dolor neuropatico.
SE9803155D0 (sv) A new composition
NO20050279D0 (no) Ny fremgangsmate